Home Cart Sign in  
Chemical Structure| 1038915-73-9 Chemical Structure| 1038915-73-9

Structure of Niraparib tosylate
CAS No.: 1038915-73-9

Chemical Structure| 1038915-73-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50 values of 3.8 nM and 2.1 nM, respectively. Niraparib tosylate inhibits DNA damage repair, activates apoptosis, and shows anti-tumor activity.

Synonyms: MK-4827 tosylate; MK-4827 (tosylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Niraparib tosylate

CAS No. :1038915-73-9
Formula : C26H28N4O4S
M.W : 492.59
SMILES Code : O=C(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C12)N.O=S(C5=CC=C(C)C=C5)(O)=O
Synonyms :
MK-4827 tosylate; MK-4827 (tosylate)
MDL No. :MFCD28167748
InChI Key :LCPFHXWLJMNKNC-PFEQFJNWSA-N
Pubchem ID :78357761

Safety of Niraparib tosylate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H340
Precautionary Statements:P260-P264-P270-P280-P281-P330-P301+P312-P405-P501

Related Pathways of Niraparib tosylate

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • PARP1

    PARP1, IC50:3.8 nM

  • PARP2

    PARP2, IC50:2.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 50 nM 24 h To evaluate the effect of Niraparib combined with CDK4/6 inhibitors on DNA damage in RB-proficient cells. The results showed that the combination significantly increased the number of γ-H2AX foci, indicating increased DNA damage. PMC7136254
MDA-MB-468 50 nM 24 h To evaluate the effect of Niraparib combined with CDK4/6 inhibitors on DNA damage in RB-deficient cells. The results showed that the combination significantly increased the number of γ-H2AX foci, indicating increased DNA damage. PMC7136254
SNU-251 100 nM To evaluate the effect of Niraparib on SNU-251 cells, results showed that SNU-251 cells formed fewer colonies in the presence of Niraparib. PMC6906494
HeLa LT ATRX knockout clones 5 µM 48 h Through C-circle assay and APB analysis, it was found that Niraparib treatment of ATRX knockout HeLa LT cells induced an increase in ALT markers, indicating that Niraparib induces the ALT pathway by trapping PARP1 protein. PMC10359465
MDA-MB-231 cells 12.5 µM 4, 8 or 24 h To study the effect of Niraparib on the transcriptomic dynamics of MDA-MB-231 cells, revealing heterogeneous responses after drug treatment. PMC8022202
RMC2C 10 μM 120 h To evaluate the inhibitory effect of Niraparib on RMC2C cells PMC7288373
RMC219 10 μM 120 h To evaluate the inhibitory effect of Niraparib on RMC219 cells PMC7288373

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice A2780wt or A2780/P-gp ovarian cancer model Oral 50 mg/kg Single dose, euthanized 2h after treatment To study the tumor distribution of Niraparib in ovarian cancer models, results showed homogeneous distribution in A2780wt tumors and heterogeneous distribution in A2780/P-gp tumors PMC7085221
Mice A2780wt and A2780/P-gp ovarian cancer models Oral 50 mg/kg Single dose, euthanized 2 hours post-treatment To study the tumor distribution of Niraparib in ovarian cancer models, results showed homogeneous distribution in A2780wt model and heterogeneous distribution in A2780/P-gp model PMC7085221
Mice MC38 subcutaneous tumor model Oral 4 mg/kg Once daily for several days To evaluate the effect of Niraparib in enhancing immune response during radiotherapy, results showed that Niraparib increased the production of Ifnb and Cxcl10. PMC9675814
Nude mice MDA-MB-231 and MDA-MB-468 xenograft models Oral 4 mg/kg Twice daily, until tumors reached 1200 mm³ or showed necrosis To evaluate the anti-tumor effect of Niraparib combined with CDK4/6 inhibitors in RB-proficient and RB-deficient xenograft models. The results showed that the combination significantly reduced tumor volume and was well tolerated. PMC7136254
Mice Patient-derived tumor xenografts (PDXs) from breast cancer patients Oral 50 mg/kg or 75 mg/kg Daily for 28 days To evaluate the antitumor activity of Niraparib in breast cancer PDX models, results showed significant antitumor effects in some models. PMC6284440
Mice NSG mice Oral 150 mg/kg Twice daily for 10 days To evaluate the effect of Niraparib on tumor growth in mice, results showed that Niraparib significantly delayed tumor growth. PMC6906494
Mice RMC2X PDX model Oral 50 mg/kg Once daily for 25 days To evaluate the antitumor effect of Niraparib on the RMC2X PDX model PMC7288373

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.15mL

2.03mL

1.02mL

20.30mL

4.06mL

2.03mL

References

 

Historical Records

Categories